On The Other Hand......GUD can acquire the remaining 71.7% of Medison that it does not already own for about $200 million or so.
xxxxxxxxxxxxxxxxxxxxxx
Mr. Jeffrey Kadanoff reports
KNIGHT TAKES ITS DOSE OF MEDISON
Knight Therapeutics Inc. has closed its previously announced transaction with Medison Biotech (1995) Ltd., Israel's leading independent specialty pharmaceutical company.
To solidify the strategic collaboration between the companies, Knight has acquired a 28.3-per-cent equity interest in Medison valued at $80-million ($60-million (U.S.)) in exchange for approximately a 10-per-cent equity interest in Knight (10.33 million common shares of Knight held by Medison and its controlling shareholder). Up to an additional 660,000 Knight shares may be issued if Medison meets certain financial targets over the next two years.